MLYS Mineralys Therapeutics, Inc.

Nasdaq mineralystx.com


$ 41.98 $ -1.33 (-3.07 %)    

Wednesday, 22-Oct-2025 15:59:53 EDT
QQQ $ 604.27 $ -5.89 (-0.96 %)
DIA $ 464.98 $ -3.44 (-0.73 %)
SPY $ 666.76 $ -3.49 (-0.52 %)
TLT $ 92.19 $ 0.06 (0.07 %)
GLD $ 376.01 $ 0.04 (0.01 %)
$ 42.04
$ 43.00
$ 35.35 x 75
$ 44.50 x 1,000
$ 40.62 - $ 43.39
$ 8.24 - $ 44.80
970,461
na
2.79B
$ 1.54
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 02-12-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-15-2023 12-31-2022 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 mineralys-therapeutics-presents-phase-2-explore-ckd-trial-of-lorundrostat-at-asn-kidney-week-2025

~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertensio...

 wells-fargo-maintains-overweight-on-mineralys-therapeutics-raises-price-target-to-50

Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price targe...

 goldman-sachs-maintains-buy-on-mineralys-therapeutics-raises-price-target-to-52

Goldman Sachs analyst Richard Law maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from...

 hc-wainwright--co-reiterates-buy-on-mineralys-therapeutics-maintains-42-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $4...

 mineralys-therapeutics-presents-subgroup-data-from-phase-3-launch-htn-trial-at-aha-2025-highlighting-lorundrostats-efficacy-in-high-risk-hypertension-populations

~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with un...

 jefferies-maintains-hold-on-mineralys-therapeutics-raises-price-target-to-26

Jefferies analyst Dennis Ding maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Hold and raises the price target from $1...

 mineralys-therapeutics-suspends-prospectus-supplement-for-atm-equity-offering

-SEC Filing

 mineralys-therapeutics-commences-175m-public-offering-with-2625m-over-allotment-option

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to targe...

 b-of-a-securities-maintains-buy-on-mineralys-therapeutics-raises-price-target-to-43

B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price targe...

 hc-wainwright--co-reiterates-buy-on-mineralys-therapeutics-maintains-42-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $4...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION